RESEARCH

IGF1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal

Anastasia Ibba¹, Francesca Corrias², Chiara Guzzetti¹, Letizia Casula¹, Mariacarolina Salerno³, Natacia di Iorgi¹,⁵, Gianluca Tornese², Giuseppa Patti²,⁵, Giorgio Radetti⁶, Mohamad Maghnie⁴,⁵, Marco Cappa⁷ and Sandro Loche¹

¹SSD Endocrinologia Pediatrica e Centro Screening Neonatale, Ospedale Pediatrico Microcitemico ‘A. Cao’, AO Brotzu, Cagliari, Italy
²SSD Endocrinologia Pediatrica, Clinica Pediatrica, IRCCS Materno-infantile Burlo Garofolo, Trieste, Italy
³Dipartimento di Pediatria, Universita Federico II, Napoli, Italy
⁴Dipartimento di Pediatria, IRCCS Istituto Giannina Gaslini, Universita di Genova, Genova, Italy
⁵Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-infantili, Universita di Genova, Genova, Italy
⁶Dipartimento di Pediatria, Ospedale Generale Regionale, Bolzano, Italy
⁷UOC di Endocrinologia, Dipartimento Universitario Ospedaliero, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy

Correspondence should be addressed to S Loche: sandro.loche@aob.it

Abstract

A number of studies have evaluated the role of IGF1 measurement in the diagnosis of growth hormone deficiency (GHD). This study aimed to evaluate the accuracy and the best cut-off of IGF1 SDS in the diagnosis of GHD in a large cohort of short children and adolescents. One-hundred and forty-two children and adolescents with GHD ((63 organic/genetic (OGHD), 79 idiopathic (IGHD)) and 658 short non-GHD children (median age 10.4 years) were included in the analysis. The two groups were subdivided according to age (G1 <6, G2 6 <9, G3 9 <12, G4 ≥12) and to pubertal status. Serum IGF1 was measured by the same chemiluminescence assay in all samples and expressed as age- and sex-based SDS. Receiver operating characteristic (ROC) analysis was used to evaluate the optimal IGF1 SDS cut-off and the diagnostic accuracy. Median IGF1 SDS was significantly lower in the GHD than in non-GHD patients. The area under the curve (AUC) was 0.69, with the best IGF1 cut-off of −1.5 SDS (sensitivity 67.61%, specificity 62.62%). The AUC was 0.75 for OGHD and 0.63 for IGHD. The accuracy was better in the pubertal (AUC = 0.81) than the prepubertal group (AUC = 0.64). In our cohort, IGF1 measurement has poor accuracy in discriminating GHD from non-GHD. Our findings confirm and reinforce the belief that IGF1 values should not be used alone in the diagnosis of GHD but should be interpreted in combination with other clinical and biochemical parameters.

Introduction

The diagnosis of growth hormone deficiency (GHD) in childhood and adolescence is based on auxological, biochemical, neuro-radiological, and genetic investigations. Since GH production is pulsatile, its secretion needs to be assessed by provocative tests. A number of different GH secretagogues and testing modalities have been proposed over the last decades (1, 2). However, their interpretation remains problematic for many reasons (3, 4). Pharmacological stimuli are not physiological, the diagnostic cut-off is often arbitrarily established, testing modalities and GH assays are widely variable among different centres. Furthermore, GH secretion may be influenced by factors such obesity, undernutrition, sex, age and puberty (4, 5). Finally, provocative tests are time-consuming, costly and entail discomfort for the patients.
The decision to perform a GH stimulation test should be based on the severity of short stature, height velocity, medical history and physical examination findings. The diagnostic cut-off for the stimulated GH peak was initially set at 5–7 μg/L, subsequently was arbitrarily increased to 10 μg/L (6, 7, 8, 9, 10, 11, 12). In the most recent guidelines (1) it has been set at 7 μg/L. We have also shown that the best GH peak cut-off ranges from 5.1 to 6.8 μg/L, depending on the stimulation test (13).

Measurement of IGF1 is also an important step in the diagnostic process (10, 14). IGF1 is a small polypeptide hormone, whose synthesis in the liver is stimulated by GH. IGF1 circulates primarily bound to the acid-labile subunit (ALS) and the insulin growth factor binding protein-3 (IGFBP3) (4, 5, 15). IGF1 and IGFBP3 serum levels show little circadian variation, so that a single measurement is more reliable than a single basal GH value. However, IGF1 and IGFBP3 levels are also influenced by the type of assay (16), the patients’ nutritional status, the presence of chronic illness or organ failure (4, 5, 16), and vary with age and pubertal status. A number of studies have investigated the role of IGF1 in the diagnosis of GHD during the past decades (1, 4, 14, 15, 17, 18, 19, 20, 21, 22) but the results are often not comparable (14, 17). Overall, these studies show that IGF1 measurement has a good specificity (around 90%) and low sensitivity (around 70%), indicating that IGF1 levels below the reference range (<−2SDS) are highly predictive of GHD but that levels within the reference range do not exclude GHD.

In the current retrospective study we aimed to define the best IGF1 SDS diagnostic cut-off using a standardized assay in a large cohort of children and adolescents with short stature. Furthermore, we wanted to evaluate through receiver operating characteristic (ROC) curve analysis (23) the accuracy of a single IGF1 measurement in the diagnosis of GHD.

### Subjects

Data from 847 children and adolescents followed in six Italian Paediatric Endocrine Units (Bolzano, Cagliari, Genova, Napoli, Roma, Trieste) for short stature and/or growth deceleration between 2005 and 2019 were reviewed in this retrospective analysis. Written consent has been obtained from each subject after full explanation of the purpose and nature of all procedures used. The study was approved by the Independent Ethical Committee of the University Hospital of Cagliari (PG/2019/8866). Forty-seven patients were excluded because they were affected by an additional pathology or for incomplete data. All 800 subjects included in the study (476 boys, 324 girls, median age 10.4 years (7.07–12.70) Tanner 1–5) underwent diagnostic procedures to evaluate a possible GHD. The entire cohort was divided into two groups of GHD and non-GHD subjects. GHD was diagnosed in 142 patients with a GH peak response <7 μg/L after two provocative tests. This group was then divided into two groups according to the etiology of GHD, organic/genetic GHD (OGHD, medulloblastoma (n=3), germinoma (n=9), craniopharyngioma (n=19), astrocytic tumors (n=5), ectopic posterior pituitary and/or empty sella and/or pituitary ipoplasia (n=26), genetic (n=1)) and idiopathic GHD (IGHD).

The 658 subjects with a GH peak ≥7 μg/L and no other recognizable endocrine cause for the short stature were considered non-GHD and served as controls. Then, the GHD and non-GHD groups were subdivided into four groups according to age (G1 <6, G2 6 <9, G3 9 <12, G4 ≥12). In order to analyse the influence of puberty on IGF1, the entire cohort was also subdivided into two groups according to the Tanner stage (prepubertal/Tanner I and pubertal/Tanner 2–5) and analysed separately comparing prepubertal (n=102) vs pubertal (n=40) GHD children and prepubertal (n=527) vs pubertal (n=128) non-GHD children. The main auxological characteristics of the subjects are summarized in Table 1.

### Methods

Clonidine and arginine stimulation tests and insulin tolerance test (ITT) were randomly used to evaluate GH reserve. According to our previous findings (13), a cut-off of 7 μg/L was adopted as the lowest limit for the GH peak. All children with GH peak <7 μg/L after the first test underwent a second stimulation test on a separate day (at least 2 days apart). All the tests were performed in the morning (08:00–09:00 h) after overnight fasting as previously described (13). Steroid priming was never used. Brain MRI was performed in all children with GHD. IGF1 was determined at baseline in all subjects at the moment of first testing.

### Assay

Serum IGF1 and GH were measured in all subjects by chemiluminescent immunometric assay (CLIA) (Inmulite 2000; Diagnostic Products Corp., Los Angeles, CA, USA). IGF1 assay was calibrated against the WHO IRR 87/518. GH assay was calibrated against the recommended IS 98/574.
**Table 1** Main clinical and laboratory characteristics of the cohort studied.

| Subjects (n) | Total     | GHD        | Non-GHD     | P-value |
|-------------|-----------|------------|-------------|---------|
| Subjects    | 800       | 142        | 658         |         |
| Age (years) | 10.4 (7.1 to 12.7) | 10.9 (8.1 to 12.7) | 10.3 (6.8 to 12.7) | 0.1149 |
| M/F         | 476/324   | 77/65      | 399/259     |         |
| Height SDS  | −2.47 (−2.84 to 2.0) | −2.3 (−1.77 to 2.9) | −2.5 (−2.8 to 2.05) | <0.0001 |
| BMI SDS     | −0.75 (−1.53 to 0.06) | 0.08 (−0.9 to 0.96) | −0.89 (−1.64 to 0.18) | <0.0001 |
| IGF1 µg/L   | 133.5 (83 to 196) | 106 (59.7 to 147) | 140.5 (90.25 to 207.8) | <0.0001 |
| IGF1 SDS    | −1.27 (−2.07 to 0.41) | −1.97 (−2.77 to 1.15) | −1.13 (−2.0 to 0.29) | <0.0001 |
| Prepubertal | 592       | 102        | 490         |         |
| Pubertal    | 110       | 40         | 70          |         |
| Prepubertal | 77/65     | 38         | 64          |         |
| Pubertal    | 110       | 40         | 70          |         |

All values are reported as median and interquartile range (IQR).

The sensitivity of the method was 2.6 nmol/L for IGF1 and 0.01 µg/L for GH. The IGF1 intra- and inter-assay coefficients of variation were 3.4 and 7.1%, respectively. The GH intra- and inter-assay coefficients of variation were, respectively, 4.2–6.6 and 2.9–4.6% at GH levels of 2.6–17 µg/L. Consistency of assay performance was assessed by regular use of internal controls.

**Statistical analysis**

Age and sex-based IGF1 SDS values were calculated using the normative data for the method (24) according to the following formula: IGF1 SDS (Z-score) = (log IGF1 ng/L – log mean for age and sex)/log mean s.d. Height SDS and BMI SDS were derived from the Italian reference data (25). Height velocity SDS was derived from Tanner’s charts (26).

Kolmogorov–Smirnov test was used to evaluate the distribution of the data. Comparison between groups was performed using the Student’s t-test and the Mann–Whitney U-test for normally distributed variables and for not-normally distributed variables, respectively. ROC analysis (23) was used to evaluate the optimal IGF1 SDS cut-off (best pair sensitivity and specificity values) and the diagnostic accuracy of IGF1 for all the groups considered. The best pair sensitivity and specificity values were calculated according to the Youden index. The area under the curve (AUC) was used to measure the accuracy of the test and was considered with 95% CI. Likelihood ratios for a positive test result (LR+), and the efficiency (Ef, the number of correct results divided by the total number of tests) were provided as a measure of diagnostic accuracy. All values were reported as median and interquartile range (IQR) (continuous variables) or as counts and percentages (categorical variables). Sensitivity, specificity, positive and negative predictive values (PPV and NPV) were expressed as percentage. P < 0.05 (two sided) was considered significant. All statistical calculations were performed using GraphPad Prism version 8.4 software, Inc.

**Results**

The clinical and biochemical characteristics of the subjects are summarized in **Table 1**. Height SDS was similar in the two groups, while, as expected, BMI SDS was higher in the GHD group. The median IGF1 SDS was −1.97 (−2.77 to 1.15) and −1.13 (−2.0 to 0.29) in GHD and non-GHD subjects, respectively (**Table 1**). The median IGF1 SDS was similar between prepubertal GHD (−1.94, −2.56 to 0.92) and pubertal GHD (−2.02, −3.32 to 1.43), while it was significantly higher in pubertal GHD (−0.73, −1.56 to 0.16) than in prepubertal non-GHD (−1.0, −1.9 to 0.2) (**Table 2**). IGF1 SDS was significantly lower in prepubertal GHD (−1.94, −2.56 to 0.92) and pubertal GHD (−2.02, −3.3 to 1.4) than in prepubertal non-GHD (−1.2, −2 to 0.4) and pubertal non-GHD (−0.73, −1.56 to 0.16), respectively (**Table 2**).

**ROC curve analyses**

The results of the ROC analyses are reported in **Figs 1, 2, 3 and Tables 3, 4, 5**.

The AUC (measure of discriminative ability of the test) for IGF1 SDS was 0.69 (95% CI: 0.64–0.74). The best pair of values for Se and Sp (67.61 and 62.62%, respectively) was found at the cut-off of −1.5 SDS (LR+ 1.80, efficiency: 67.6%, PPV: 28.07%, NPV: 89.95%). Thus, using the IGF1 SDS cut-off −1.5 a correct diagnosis was possible in 96 GHD patients (67.6% (n = 47 OGHD, n = 49 IGHD)) and 412 non-GHD subjects (62.61%). At the IGF1 cut off −2 SDS, Sp and Se were 46.4 and 77.2%, respectively, with a LR+ of 2 and Ef of 63%, PPV 30%, NPV 86%.
Table 2  Differences between groups according to pubertal status.

| IGF1 SDS | Prepubertal | Pubertal | P-value |
|----------|-------------|----------|---------|
| GHD (n)  | 102         | 40       | 0.114   |
| −1.94 (−2.56 to 0.92) | −2.02 (−3.32 to 1.43) |         |
| Non-GHD (n) | 527        | 128      | 0.001   |
| −1.2 (−2 to 0.4) | −0.73 (−1.56 to 0.16) | <0.0001 |
| P-value  | <0.0001     | <0.0001  |         |

All values are reported as median and interquartile range (IQR). GHD, growth hormone deficiency; IGF1, insulin-like growth factor 1; SDS, standard deviation score.

The AUC for OGHD IGF1 SDS was 0.75 (95% CI: 0.69–0.82) with IGF1 SDS best cut-off of −1.71 (Se: 74.6% and Sp: 67.33%; LR+: 2.28, Ef: 66%, PPV: 18.3%, NPV: 95.06%). The AUC for IGHD IGF1 SDS was 0.63, best cut-off was −1.51 SDS (Se: 62.03%, Sp: 62.92%, LR+: 1.67, Ef: 62.02%, PPV: 16.2%, NPV: 93.04%). The best IGF1 SDS cut-off to discriminate between non-GHD and OGHD groups was −1.71 (Se: 74.6% and Sp: 67.33%; LR+: 2.28, Ef: 67.4%, PPV: 17.66%, NPV: 96.48%). The accuracy of the IGF1 SDS for GHD was demonstrated by an AUC of 0.75, best cut-off of −1.71 SDS (Se: 74.6% and Sp: 67.33%; LR+: 2.28, Ef: 66%, PPV: 18.3%, NPV: 95.06%). The AUC for IGHD IGF1 SDS was 0.63, best cut-off was −1.51 SDS (Se: 62.03%, Sp: 62.92%, LR+: 1.67, Ef: 62.02%, PPV: 16.2%, NPV: 93.04%). The best IGF1 SDS cut-off to discriminate between non-GHD and OGHD groups was −1.71 (Se: 74.6% and Sp: 67.33%; LR+: 2.28, Ef: 66%, PPV: 18.3%, NPV: 95.06%). The AUC for IGHD IGF1 SDS was 0.63, best cut-off of 1.5 SDS. Cianfarani et al. (34) evaluated 33 GHD and 56 subjects with idiopathic short stature (non-GHD) and found that the IGF1 SDS cut-off of −1.9 best discriminated GHD from idiopathic short stature, with 73% sensitivity and 95% specificity. Boquete et al. (29) studied 67 subjects and found that −1.65 SDS was the best IGF1 cut-off to discriminate GHD from idiopathic short stature with sensitivity and specificity of 68 and 97%, respectively. Binder et al. (32) proposed reference range for IGF1 SDS with the purpose to screen short children for GHD. They considered −1.4 SDS as the best cut-off with 100% of sensitivity, but poor specificity (33.3%). Furthermore, using ROC analysis they found an AUC of

Figure 1
ROC curve for IGF1 SDS.

Discussion

The aim of our study was to investigate the predictive value of a single IGF1 measurement in the diagnosis of GHD in a large and well-selected cohort of children and adolescents with short stature using the same IGF1 assay. Since 1982, IGF1 measurement has been proposed as an alternative to GH stimulation testing for assessing GH status in short children because it is easier to perform and more reproducible (27). The usefulness of IGF1 measurement, alone or in combination with IGFBP3,
0.8 for IGF1 SDS. In contrast we found a lower AUC with a specificity twice as high for a similar cut-off of −1.5 SDS.

Despite the high specificity, most authors concluded that IGF1 measurement is useful in the diagnosis of GHD only when combined with auxological parameters and the results of GH stimulation testing (14, 18, 20, 29, 32, 34).

We have previously shown that IGF1 measurement combined with GH provocative testing, increases the specificity of the test results, reaching 95.8% for ITT, 98.4% for clonidine test, 95.6% for arginine test, and reduces the risk of false positive results (13). In addition, our results indicate that the accuracy of IGF1 measurement is slightly better in the 6–9 years group, although sensitivity and specificity remained around 70%. According to Cianfarani et al. (40), specificity was higher in children younger than 11, reaching 91%. In our cohort we observed that specificity was higher in the ≥12 years group (91.5%) coupled with the highest diagnostic efficiency (82%) with a best cut off of −3 SDS, but still with suboptimal accuracy (AUC=0.72).

|                  | GHD vs non-GHD | Non-GHD vs OGHD |
|------------------|---------------|-----------------|
| AUC              | 0.69          | 0.75            |
| Best cut-off (SDS)| −1.5          | −1.71           |
| Sensitivity (%)  | 67.61         | 74.6            |
| Specificity (%)  | 62.62         | 67.33           |
| Efficiency (%)   | 67.6          | 67.4            |
| LR+              | 1.80          | 2.28            |
| PPV (%)          | 28.07         | 17.66           |
| NPV (%)          | 89.95         | 96.48           |
| Cut-off for sensitivity at 95% | −0.13 | −0.23 |
| Cut-off for specificity at 95% | −3.08 | −3.38 |

AUC, area under the curve; GHD, growth hormone deficiency; IGF1, insulin-like growth factor 1; LR+, positive likelihood ratio; NPV, negative predictive value; OGHD, organic/ genetic growth hormone deficiency; PPV, positive predictive value; SDS, standard deviation score.
Puberty has a profound influence on the GH–IGF1 axis. At the time of puberty, an increase in GH release follows the increased secretion of sex steroids (41). Twenty-four-hour GH concentration and, consequently, IGF1 concentrations, increase during puberty, either spontaneous, precocious or pharmacologically induced (41, 42). This was confirmed in our cohort, as the IGF1 concentrations rose with puberty in the non-GHD children.

We also found significant differences in IGF1 values between the OGHD and IGHD group, with best discriminative cut-off of −2.65 SDS, confirming that patients with organic and genetic GHD (i.e. usually severe GHD) have lower IGF1 values than patients with idiopathic GHD (14, 43, 44, 45, 46).

This study has the inherent limitations of all retrospective studies. Furthermore, the non-GHD group may be heterogeneous and include patients with subtle alterations of GH secretion or partial GH resistance. Likewise, some patients classified as IGHD may indeed be non-GHD subjects with falsely positive results to two stimulation tests (47). However, to our knowledge, this is the first study performed on a large well-selected population of short children and adolescents using the same IGF1 assay and a robust statistical method. In addition, the data have been obtained and analysed from the real clinical settings.

In conclusion, this study shows that the IGF1 value of −1.5 SDS is the best cut-off to discriminate between GHD and non-GHD. Slight better accuracy was observed for patients aged 6–9 years, for the organic/genetic GHD group and for the pubertal group. The results of this study also confirm that IGF1 values must be interpreted in combination with other clinical and biochemical parameters for the diagnosis of GHD.

### Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### Funding
This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

### References
1. Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Cheung PT, Choong CSV, Cohen LE, Cohen P, et al. Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics 2019 92 1–14. ([https://doi.org/10.1159/000502231](https://doi.org/10.1159/000502231))
2. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM & 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. Journal of Clinical Endocrinology and Metabolism 2008 93 4210–4217. ([https://doi.org/10.1210/jc.2008-0809](https://doi.org/10.1210/jc.2008-0809))
3. Murray PG, Dattani MT & Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Archives of Disease in Childhood 2016 101 96–100. ([https://doi.org/10.1136/archdischild-2014-307228](https://doi.org/10.1136/archdischild-2014-307228))
4. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry 2011 57 555–559. ([https://doi.org/10.1373/clinchem.2010.150631](https://doi.org/10.1373/clinchem.2010.150631))
IGF1 in growth hormone deficient children

5 Schilbach K & Bidlingmaier M. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Archives of Endocrinology and Metabolism 2019 63 618–629. (https://doi.org/10.20945/2359-3997000000192)

6 Kaplan SL, Abrams CAL, Bell JJ, Conte FA & Grumbach MM. Serum growth hormone response to insulin-induced hypoglycemia in disorders of growth. Journal of Pediatrics 1965 67 956–959. (https://doi.org/10.1016/S0022-3476(65)81883-2)

7 Frohman LA, Aceto T & MacGillivray MH. Studies of growth hormone secretion in children: normal, hypopituitary and constitutionally delayed. Journal of Clinical Endocrinology and Metabolism 1967 27 1409–1417. (https://doi.org/10.1210/jcem-27-10-1409)

8 Raiti S, Davis WT & Blizzard RM. A comparison of the effects of insulin hypoglycemia and arginine infusion on release of human growth hormone. Lancet 1967 290 1182–1183. (https://doi.org/10.1016/S0140-6736(67)91896-X)

9 Root AW, Saenz-Rodriguez C, Bongiovanni AM & Eberlein WR. The effect of arginine infusion on plasmagrowth hormone and insulin in children. Journal of Pediatrics 1966 74 187–197. (https://doi.org/10.3121/jcem.74.3.187)

10 Frasier SD. The serum growth hormone response to hypoglycemia in dwarfs. Journal of Pediatrics 1967 71 625–638. (https://doi.org/10.3121/jcem.71.5.625)

11 GH Research Society. Consensus guidelines for the diagnosis and follow-up of GH-related disorders. Journal of Clinical Endocrinology and Metabolism 2000 85 3990–3993. (https://doi.org/10.1210/jcem.85.11.6984)

12 Rosenfield RG. Is growth hormone deficiency a viable diagnosis? Journal of Clinical Endocrinology and Metabolism 1997 82 349–351. (https://doi.org/10.1210/jcem.82.2.8341)

13 Guzzetti C, Ibba A, Pilla S, Beltrami N, Di Iorgi N, Rollo A, Fratangelii N, Radetti G, Zucchinii S, Maghnie M, et al. Cut-off limits of the peak GH response to stimulation tests for the diagnosis of GH deficiency in children and adolescents: study in patients with organic GDH. European Journal of Endocrinology 2016 175 41–47. (https://doi.org/10.1530/EJE-16-0105)

14 Federico G, Street ME, Maghnie M, Caruso-Nicoletti M, Loche S, Bertelloni S, Cianfarani S, Study Group on Physiopathology of Pediatric Endocrinology and Diabetes (SIEPD/ISPED). Assessment of serum IGF-I concentrations in the diagnosis of isolated childhood-onset GH deficiency: a proposal of the Italian Society for Pediatric Endocrinology and Diabetes (SIEPD/ISPED). Journal of Endocrinological Investigation 2006 29 732–737. (https://doi.org/10.1007/BF03344156)

15 Blum WF, Alberthia B, Alasghier A, El Awwa A, Kaplan W, Koleova E & Savage MO. The growth hormone–insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Lancet 2000 356 625–638. (https://doi.org/10.1016/S0140-6736(00)02415-5)

16 Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Blum WF, Alherbish A, Alsagheir A, El Awwa A, Kaplan W, Hahlgren Z & Amiri-Hakimi G. The role of insulin like growth factor (IGF-I) and IGF-binding protein-3 in diagnosis of growth hormone deficiency in short stature children. Italian Journal of Pediatrics 2009 35 699–703. (https://doi.org/10.12816/0011355)

17 Zweig MH & Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry 1993 39 561–577. (https://doi.org/10.1093/clinchem/39.4.561)

18 McElringer MW, Kühnel W, Weber MM & Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clinical Chemistry and Laboratory Medicine 2004 42 654–664. (https://doi.org/10.1515/CCLM.2004.0112)

19 Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gigantino L, Greggio N, Tonioli G, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). Journal of Endocrinological Investigation 2006 29 581–593. (https://doi.org/10.1007/BF03344156)

20 Tannen JM & Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Archives of Disease in Childhood 1976 51 170–179. (https://doi.org/10.1136/adc.51.3.170)

21 Moore DC, Ruvalcaba RHA, Smith EK & Kelley VC. Plasma somatomedin-C as a screening test for growth hormone deficiency in children and adolescents. Hormone Research 1982 16 49–55. (https://doi.org/10.1159/000179484)

22 Wang Y, Zhang H, Cao M, Kong L & Ge X. Analysis of the value of new cut-off limits for biochemical testing of GH secretion in childhood. Growth Hormone and IGF Research 2011 21 212–218. (https://doi.org/10.1016/j.ghir.2011.05.007)
33 Bogazzi F, Manetti L, Lombardi M, Giovannetti C, Raffaelli V, Urbani C, Scattina I, Pepe P, Iannelli A, Martin E, et al. Impact of different cut-off limits of peak GH after GHRH-arginine stimulatory test, single IGF1 measurement, or their combination in identifying adult patients with GH deficiency. European Journal of Endocrinology 2011 164 685–693. (https://doi.org/10.1530/EJE-10-1068)

34 Cianfarani S, Tondinelli T, Spadoni GL, Scire G, Boemi S & Boscherini B. Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clinical Endocrinology 2002 57 161–167. (https://doi.org/10.1046/j.1365-2265.2002.01591.x)

35 Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Cianfarani S, Tondinelli T, Spadoni GL, Scire G, Boemi S & Bogazzi F, Manetti L, Lombardi M, Giovannetti C, Raffaelli V, Saenger P, Bettendorf M, Zachurzok A, Gohlke B, Gondo Y, Melmed S, Urbani C, Scattina I, Pepe P, Iannelli A, Martin E, et al. Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clinical Endocrinology 2002 57 161–167. (https://doi.org/10.1046/j.1365-2265.2002.01591.x)

36 Inoue-Lima TH, Vasques GA, Scalco RC, Nakaguma M, Mendonca BR, Arnhold IJP & Jorge AAL. IGF-1 assessed by pubertal status has the best positive predictive power for GH deficiency diagnosis in peripubertal children. Journal of Pediatric Endocrinology and Metabolism 2016 29 361–397. (https://doi.org/10.1515/jpem-2018-0435)

37 Ali A, Hashim R, Khan FA, Sattar A, Ijaz A, Manzoor SM & Younas M. Evaluation of insulin-like growth factor-I and II and insulin-like growth factor binding protein-3 in diagnosis of growth hormone deficiency in short stature children. Journal of Ayub Medical College, Abbottabad 2009 21 40–45.

38 Granada ML, Murillo J, Lucas A, Salinas J, Llops MA, Castells I, Foz M & Sanmartí A. Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-II/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. European Journal of Endocrinology 2000 142 243–253. (https://doi.org/10.1530/eje.0.1420243)

39 Binder G, Reinehr T, Ibáñez L, Thiele S, Linglart A, Woelfle J, Saenger P, Bettendorf M, Zachurzok A, Gohlke B, et al. GHD diagnostics in Europe and the US: an audit of national guidelines and practice. Hormone Research in Paediatrics 2019 92 150–156. (https://doi.org/10.1159/000503783)

40 Blum WF, Böttcher C & Wudy SA. Insulin-like growth factors and their binding proteins. In Diagnostics of Endocrine Function in Children and Adolescents, pp. 157–182. Eds MB Ranke & PE Mullis. Basel, Switzerland: Karger, 2011. (https://doi.org/10.1159/000327407)

41 Loche S, Casini MR & Faedda A. The GH/IGF-I axis in puberty. British Journal of Clinical Practice: Supplement 1996 85 1–4.

42 Maurus N, Rogol AD, Raymond MW & Veldhuis JD. Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Hormone Research 1996 45 74–80. (https://doi.org/10.1159/000184763)

43 Maghnie M, Strigazzi G, Tinelli C, Autelli M, Cisternino M, Loche S & Severi F. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. Journal of Clinical Endocrinology and Metabolism 1999 84 1324–1328. (https://doi.org/10.1210/jcem.84.5.7538145)

44 Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L & Melmed S. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. Journal of Clinical Endocrinology and Metabolism 1995 80 1532–1540. (https://doi.org/10.1210/jcem.80.5.7538145)

45 Trivin C, Souberbielle JC, Aubertin G, Lawson-Body E, Adan L & Brauner R. Diagnosis of idiopathic growth hormone deficiency: contributions of data on the acid-labile subunit, insulin-like growth factor I (IGF-I) and II, and IGF binding protein-3. Journal of Pediatric Endocrinology and Metabolism 2006 19 481–489.

46 Patti G, Noli S, Capalbo D, Allegri AME, Napoli F, Cappa M, Ubertini GM, Gallizia A, Notarnicola S, Ibba A, et al. Accuracy and limitations of the growth hormone (GH) releasing hormone-arginine retesting in young adults with childhood-onset GH deficiency. Frontiers in Endocrinology 2019 10 525. (https://doi.org/10.3389/fendo.2019.00525)

47 Loche S, Bizzarri C, Maghnie M, Faedda A, Tzialla C, Autelli M, Casini MR & Cappa M. Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. Journal of Pediatrics 2002 140 445–449. (https://doi.org/10.1067/mpd.2002.122729)

Received in final form 9 October 2020
Accepted 22 October 2020
Accepted Manuscript published online 22 October 2020